Literature DB >> 26436212

Real-World Patterns of Care for the Overactive Bladder Syndrome in the United States.

Howard B Goldman1, Jennifer T Anger2, Canan B Esinduy3, Kelly H Zou3, David Russell3, Xuemei Luo3, Fady Ntanios3, Martin O Carlsson3, J Quentin Clemens4.   

Abstract

OBJECTIVE: To examine the "real-world" overactive bladder (OAB) practice patterns using national data in the United States.
MATERIALS AND METHODS: The Humedica EHR database was queried. This database consists of de-identified patient records from a network of organizations treating approximately over 30 million patients across states in the United States. The entire study period was from July 1, 2008, to September 30, 2013. Patients with a diagnosis of OAB between July 1, 2009, and June 30, 2012 were included and followed. Patient comorbidities, demographics, diagnostic testing, and medication usage were analyzed.
RESULTS: Of 19,309,600 subjects enrolled during the study period, 46,648 adults had a diagnosis of OAB, with follow-up of at least 6 months, and met the inclusion criteria. There were 35,315 women and 11,333 men. Compared with women, men with OAB were more likely to undergo post-void residual measurement (32% vs 22%) and diagnostic cystoscopy (10% vs 7%). Women were more likely than men to undergo urodynamics (7% vs 3%). Overall, 34% of women and 19% of men diagnosed with OAB were prescribed medication.
CONCLUSION: Few patients with OAB underwent invasive diagnostic testing. Anticholinergic medication was prescribed to a minority of patients diagnosed with OAB, indicating possible underuse of a potentially effective therapy. Men were less likely than women to receive medical therapy, despite the fact that OAB is common in both sexes.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26436212     DOI: 10.1016/j.urology.2015.09.025

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  6 in total

1.  Overactive bladder in men: a practical approach.

Authors:  Alexandra L Millman; Douglas C Cheung; Cian Hackett; Dean Elterman
Journal:  Br J Gen Pract       Date:  2018-06       Impact factor: 5.386

2.  Antimuscarinic Medication Use in Elderly Patients with Overactive Bladder.

Authors:  Nandita Kachru; Sneha Sura; Satabdi Chatterjee; Rajender R Aparasu
Journal:  Drugs Aging       Date:  2016-10       Impact factor: 3.923

3.  Antimuscarinic use among older adults with dementia and overactive bladder: a Medicare beneficiaries study.

Authors:  Nandita Kachru; Holly M Holmes; Michael L Johnson; Hua Chen; Rajender R Aparasu
Journal:  Curr Med Res Opin       Date:  2021-05-13       Impact factor: 2.705

4.  Cardiovascular risk profile in individuals initiating treatment for overactive bladder - Challenges and learnings for comparative analysis using linked claims and electronic medical record databases.

Authors:  E Vonesh; K L Gooch; V Khangulov; C R Schermer; K M Johnston; S M Szabo; J S Rumsfeld
Journal:  PLoS One       Date:  2018-10-16       Impact factor: 3.240

5.  [Prevalence and characterization of overactive bladder detected in a population in Madrid with self-administered OAB-V3 questionnaire in Primary Care].

Authors:  Javier C Angulo; María P Calderín; Yolanda Fernández; Miriam González; Esther Gómez; Maria B Herreros; Purificación Peñasco; Manuela Zapatero; Juan F Dorado
Journal:  Aten Primaria       Date:  2017-07-24       Impact factor: 1.137

6.  Alzheimer's disease and related dementias risk: Comparing users of non-selective and M3-selective bladder antimuscarinic drugs.

Authors:  Douglas Barthold; Zachary A Marcum; Shelly L Gray; Julie Zissimopoulos
Journal:  Pharmacoepidemiol Drug Saf       Date:  2020-08-27       Impact factor: 2.732

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.